Search peptides, terms, sources/
Research source · 2026

Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials

About this source

Kind
Research
Design
Human clinical trial, RCT
Population
3,808 adults, 55 to 85, early-stage symptomatic Alzheimer's disease, amyloid-confirmed
Sample size
3808
Primary or secondary
primary
Peer review
peer reviewed
Retraction status
None known
Date checked
14 August 2026

Limitations

Negative primary-endpoint result; sponsor-funded.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.